complex. Narrow profit margins for generic drugs have limited the incentive to produce them. Other reasons include the limited num ber of manufacturers, increased worldwide demand, shortages of raw materials, production prob lems, aging production plants, stockpiling, and long timelines for approval. 1 Patient care may suffer significantly as a result: alternative drugs must be pre scribed, but the replacement may be less efficacious, more toxic, prohibitively expensive, or all of the above, and safety may be com promised if providers are unfa miliar with administering the sub stitute.
Shortages of anticancer agents are even more critical, because there may be no equivalents for the drugs that are in short supply, and conversion factors and dose adjustments may be unknown. Recent media coverage has high lighted shortages of cytarabine, daunorubicin, and methotrexate, which are essential for treating childhood leukemia, a highly cur able cancer. Fortunately, those shortages were quickly resolved, and alternative strategies such as prioritizing patients for access to certain drugs and using equiv alent agents sufficed to bridge the gap.
One shortage that hasn't made the news is that of mechloretha mine, or nitrogen mustard, one of the first anticancer agents, which was used in the 1960s in combi nation with vincristine, procar bazine, and prednisone in the MOPP regimen for Hodgkin's lymphoma. Although this regi men was effective, it was associ ated with secondary leukemia and infertility. Alternative che motherapy combinations were developed to avoid these compli cations. In an effort to maintain excellent outcomes while mini mizing toxicity, a 12week chemo therapy regimen was developed at Stanford University (the Stanford V regimen) that included vinblastine, mechlorethamine, doxorubicin, vin cristine, bleomycin, etoposide, and prednisone. This regimen's main features are an abbreviated course of treatment, unchanged or increased dose intensity of in dividual drugs, lower cumulative doses of bleomycin and doxorubi cin than in other standard regi mens, exposure to lower cumu lative mechlorethamine than in MOPP, and omission of procarba phosphamide at a dose of 650 mg per square meter of bodysurface area could safely be substituted for mechlorethamine 6 mg per square meter. When mechlor ethamine became unavailable, we amended our studies to use cyclo phosphamide instead. Although the COPP regimen (cyclophos phamide 600 to 650 mg per square meter, vincristine, pro carbazine, and prednisone) has been widely used in adult and pediatric trials and was believed to be equivalent in efficacy to MOPP, no randomized study had ever compared the two.
Many published reports de scribe in detail the sources of drug shortages, as well as reac tions of the Food and Drug Ad ministration, the American Society of Clinical Oncology, or Congress. Other reports speculate on pos sible solutions, but few comment on individual patient safety. 2,3 Al though concerns have been raised about reduced efficacy and pos sible adverse outcomes related to shortages of anticancer agents, we have seen no report documenting the adverse effects of these short ages on a specific patient popu lation or the way in which a sub stitution has affected outcomes.
To assess the impact of the sub stitution that we were forced to adopt, we compared the probabil ity of eventfree survival among 181 patients who were treated with the original Stanford V reg imen including mechlorethamine with the probability among 40 pa tients treated with the modified Stanford V regimen including cy clophosphamide. In this retrospec tive comparison, we discovered that treatment with cyclophos phamide was significantly less ef fective (2year eventfree survival, 75% with cyclophosphamide [SE, 12.5%] vs. 88% with mechloreth amine [SE, 2.5%; P = 0.01 by the logrank test]) (see graph). We can think of no credible explanation for this dramatic difference in eventfree survival other than the drug substitution, since careful analysis of our data demonstrat ed that patients in the cyclophos phamide cohort did not have more unfavorable clinical features than those in the mechlorethamine cohort. In fact, patients in the cy clophosphamide cohort were less likely to have B symptoms (fever, unintentional weight loss, and night sweats) and more likely to have intermediaterisk or high risk Hodgkin's lymphoma, with no difference in mediastinal bulk or stage distribution.
Followup is still short (median followup, 1.5 years in the cyclo phosphamide group and 4.7 years in the mechlorethamine group), and no patient in the study has died, so there is no survival dif ference between the cohorts. However, patients who had a re lapse received salvage therapy in cluding intensive cytoreduction followed by autologous stemcell Two-year event-free survival was 75% among patients who received cyclophosphamide (SE, 12.5%) and 88% among those who received mechlorethamine (SE, 2.5%; P = 0.01).
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Withdrawal of Generic Budeprion for Nonbioequivalence
Janet Woodcock, M.D., Mansoor Khan, R.Ph., Ph.D., and Lawrence X. Yu, Ph.D.
T he Food and Drug Adminis tration (FDA) has completed a headtohead bioequivalence study of single doses of the generic drug Budeprion XL 300 mg (extended release bupropion hydrochloride, manufactured by Impax Labora tories and distributed by Teva Pharmaceuticals) and the brand name drug Wellbutrin XL 300 mg (Biovail). The agency has conclud ed that Budeprion XL 300 mg can not be considered therapeutically equivalent to the brandname product. We at the FDA are there fore changing our bioequivalence recommendations for extended release bupropion products and have asked other manufacturers of 300mg extendedrelease bu propion products to conduct ad ditional bioequivalence studies.
Within a year after gaining approval at the end of 2006, Budeprion XL 300 mg became the subject of intense media cover age describing adverse events in patients being treated for major depressive disorder who had switched to the generic drug from Wellbutrin XL. Approval of Bude prion XL 300 mg was based on the results of a bioequivalence study of Budeprion XL 150 mg and Wellbutrin XL 150 mg, which were extrapolated to the 300mg product. Our new data provide direct comparative pharmacoki netic analyses of the 300mg products.
According to current guidance from the FDA Center for Drug Evaluation and Research, conclu sions that two drug products are bioequivalent should reflect sig nificant agreement in pharmaco kinetic parameters such that the entire 90% confidence interval associated with the genericto reference ratio of geometric means should fall within the bioequiv alence limits of 80 to 125%. 1 Budeprion XL 300 mg did not meet these criteria in our bio equivalence study, which involved 24 healthy fasting volunteers and used a singledose crossover de sign (see graph). The extent of bupropion absorption after the administration of the generic product, as reflected in the area under the curve of the plasma concentrations plotted over time, was 86% of the absorption with the brandname product (see graph), but the corresponding 90% confidence interval was 77 to 96%. In addition, the mean peak plasma concentration (C max ) observed after the administration of Budeprion XL 300 mg was only 75% of that observed after the administration of Wellbutrin XL 300 mg (90% confidence in terval, 65 to 87). In certain study participants, the C max and the area under the plasmaconcen tration curve for Budeprion XL were less than 40% of the values with Wellbutrin XL. The C max values for hydroxybupropion, the major active metabolite of bu propion hydrochloride, also failed to meet the FDA bioequivalence criteria.
The other major difference observed between Budeprion XL
